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a b s t r a c t
Objective: To review the data presented in the 2021 WHO global TB report and discuss the current constraints in the global response.
Introduction and methods: The WHO global TB reports, consolidate TB data from countries and provide
up to date assessment of the global TB epidemic. We reviewed the data presented in the 2021 report.
Results: We noted that the 2021 WHO global TB report presents a rather grim picture on the trajectory
of the global epidemic of TB including a stagnation in the annual decline in TB incidence, a decline in TB
notiﬁcations and an increase in estimated TB deaths. All the targets set at the 2018 United Nations High
Level Meeting on TB were off track.
Interpretation and conclusion: The sub-optimal global performance on achieving TB control targets in
2020 is attributed to the on-going COVID-19 pandemic, however, TB programs were already off track well
before the onset of the pandemic, suggesting that the pandemic ampliﬁed an already fragile global TB
response. We emphasize that ending the global TB epidemic will require bold leadership, optimization of
existing interventions, widespread coverage, addressing social determinants of TB and importantly mobilization of adequate funding required for TB care and prevention.
© 2022 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/)
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On March 24, 2022, the world will commemorate the World TB
Day in remembrance of the day in 1882, when the German scientist, Robert Koch, gave his famous lecture in which he announced
the discovery of the pathogen that causes tuberculosis, Mycobacterium tuberculosis (Barberis, et al, 2017). It is a day for raising
awareness about TB and to reﬂect on the status of this age-old
global epidemic. This year’s theme for World TB Day is ‘Invest to
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Table 1
End TB Strategy and UNHLM Targets and progress 2015-2022
Parameter

Target

Achieved

Incidence decline (compared with 2015 baseline)
Deaths decline ( compared with 2015 baseline)
Catastrophic costs incurred by individuals with TB/their families
People treated for TB, 2018-2022
Children treated for TB, 2018-2022
People with MDR TB treated, 2018-2022
Children with MDR TB treated, 2018-2022
People treated for LTBI, 2018-2022
People living with HIV treated for LTBI, 2018-2022
Household contacts <5 years treated for LTBI, 2018-2022
Household contacts >5 years treated for LTBI, 2018-2022
Annual funding needs
Annual Research funding for TB

20%
35%
0
40 million
3.5 million
1.5 million
115,000
30 million
6 million
4 million
20 million
13 billion USD
2 billion USD

11%
9.2%
47%
19.8 million (50%)
1.4 million (41%)
483, 000 (32%0
12,200 (11%)
8.7 million (29%)
7.2 million ( >100%)
1.2 million (29%)
0.32 million (1.6%)
5.3 billion USD
901 million USD

Sourced from the WHO Global TB Report 2021.

End TB’ and it comes at a time when global TB care and prevention
efforts are being hampered by the pressures on health services due
to the COVID-19 pandemic.
The World Health Organization (WHO) annual TB Reports consolidate TB data reported to the WHO by most countries of the
world. They provide a comprehensive and up to date assessment
of the global TB epidemic. The most recent WHO global TB report
was produced in 2021 and provides data on the TB epidemic for
the year 2020 (WHO Report, 2021). This report consolidates data
submitted to WHO by 197 countries and territories covering more
than 99% of the world population. While previous WHO global TB
reports have, on the whole, provided uplifting news on the trajectory of the global burden of TB, the 2021 report is different, providing not so good news and makes grim reading.
In 2020, the world fell signiﬁcantly off track on all the United
Nations General Assembly (UNGA) targets (Sahu, et al, 2021). Thus,
the small annual decline in TB incidence that had been witnessed
over the previous years almost ground to a halt, notiﬁcations of
people with TB declined by 18% when compared with the previous year. For the ﬁrst time in 9 years the number of estimated
TB deaths increased (Table 1). TB deaths increased because of restricted access to disrupted TB services in light of the COVID-19
pandemic, resulting in almost half of the estimated persons who
fell ill due to TB not being diagnosed and treated. Furthermore, the
number of people with drug-resistant TB and LTBI receiving treatment dropped signiﬁcantly. The report also indicates that there
was a reduction in funding for TB, and BCG coverage among children. This sad state of affairs is largely attributed to the on-going
COVID-19 pandemic. As the COVID-19 pandemic established itself
in 2020, it disrupted essential health services (Migliori, et al, 2021)
including those for TB, in addition to imposing an additional health
burden to people with TB who appear to be more vulnerable to
suffering severer forms of this new infectious disease (Visca et al.,
2021; The Globle TB Study group, 2021). Indeed, the COVID-19
pandemic has highlighted the fragility of TB services globally, and
the negative consequences especially among the poor and most
disadvantaged populations. Since the COVID-19 pandemic is far
from over and continues to burden health services since the 2021
TB Report was published in August 2021, it is to be anticipated that
achieving Global TB control targets is becoming even more distant
as TB services continue to be disrupted. However, on a brighter
side, the COVID-19 pandemic has shown several potential access,
diagnostic and follow-up innovations which can be leveraged for
improvements in delivering TB services (Odhiambo, et al, 2021).
While it may be appropriate to accord the blame to the COVID19 pandemic for retarding progress towards achieving the targets
set by the World Health Assembly in 2014 and those set by world
leaders at the ﬁrst ever United Nations High Level Meeting on TB
held in September 2018, it is important to note that even before

the COVID-19 appeared, some of the targets appeared already off
track (Sahu et al, 2021; Zumla et al, 2021). The COVID-19 pandemic
storm has further aggravated the situation which calls for reﬂections on several important issues regarding a) the targets and ask
if they remain relevant and feasible, b) recommended interventions
and tools for TB care and prevention and ask if these interventions
and tools are being applied at the right level in the settings where
TB imposes its greatest toll, c) measures being taken to mitigate
social determinants of TB and d) the funding landscape for TB and
approaches in place to close TB ﬁnancing gaps.
Targets
The End TB Strategy adopted by the World Health Assembly in
2014 and which has been implemented for about six years now has
ambitious targets and was intended to end TB as a global public
health threat by 2035. If TB care and prevention progresses as outlined in the End TB Strategy the world expects to see declines in TB
incidence and mortality of 95% and 90% respectively by 2035 compared with 2015. Additionally, by now no person or family would
be incurring catastrophic costs on account of TB. Had the world
been on track to achieve these targets, by now TB incidence and
mortality would have declined by at least 20% and 35% respectively
compared to the rates in 2015. However, performance has been
sub-optimal with only an 11% decline in TB incidence and a 9.2%
decline in TB mortality by 2021. Additionally, while the UNHLM on
TB set a target of 20 million people over the age of 5 years to receive TB preventive therapy by 2022, in 2020, only 16% of people
who could have beneﬁted from this treatment had received it. Considering the current trajectory of these epidemiological indicators,
it is not unreasonable to pose a few questions: are these targets
achievable? Do we lack the necessary tools to prevent and manage
TB or are we slow in implementing them?
The interventions and tools
The epidemiological framework for the prevention and care of
TB is based on what is currently known about its transmission, the
risk of progression from infection to disease and the effect of various interventions on these processes. Interventions for the prevention and management of TB ideally should encompass measures
to: reduce exposure to Mycobacterium tuberculosis, identify all infected persons and provide preventive therapy to limit progression
to active TB disease, especially for those persons at risk for this
outcome, identify early, people with active TB and provide effective treatment to ensure relapse free cure, reduced risk of acquired
drug resistance and prevention of long term morbidity from TB
(Ozcaglar, et al, 2012; Lönnroth, et al, 2015; Carvalho, et al, 2018;
Mandal, etal, 2015) These interventions need to be applied in the
2
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context of the health care system, preferably under the umbrella
of universal health coverage and with the right level of political
commitment which then leads to the mobilization of adequate ﬁnancial resources to support care and prevention of the disease.
Pillar 1 and 2 of the End TB strategy are intended to support this
epidemiological framework for TB care and prevention. Thus, the
world appears to have an appropriate and well thought out strategy that if implemented to the full, should lead to the achievement
of the ambitious targets of the End TB strategy.
Additionally, the ﬁght against TB has been buoyed by the development and deployment of new tools. While a perfect situation
is still far away, improvements have been made in the portfolio
of TB diagnostics. In the last few years WHO has approved or endorsed new TB diagnostic tests (WHO Report, 2020), which offer
the potential for targeted treatment of people with TB as a result of up-front knowledge of anti-TB drug susceptibility proﬁles.
These advances together with the deeper understanding of host
immune responses that can be used to design host directed therapies, ability to assess and monitor drug responses and progress
with biomarker discoveries offers a real potential to provide precision medicine for TB (Lange C et al 2020). Treatment of TB and
especially treatment of drug resistant forms of TB has also advanced with medicines that have a higher eﬃcacy while also being
safer becoming available (Mirzayev et al., 2021; WHO, 2021b). Even
though progress is slow, national TB programs across the world
are increasingly taking up TB prevention through better application of infection prevention measures at health facility level and
the provision of TB preventive therapy. Advances in the development of TB vaccines is providing hope that an eﬃcacious vaccine
will become available in the period covered by the End TB Strategy
(Gopalaswamy, et al, 2022). Screening programs for active TB using highly sensitive tools is slowly gaining ground providing hope
that the paradigm to ﬁnd, treat and prevent TB will become a reality for a large proportion of people with TB across the world. We
know that when interventions are applied consistently and widely
to achieve a high population coverage, the burden of TB can be
brought down (Comstock et al 1961; Corbett et al 2010, Marks et al
2019). The challenge seems to be related to sub-optimal application of effective interventions which may have multiple origins,
with inadequate ﬁnancing being a major driver of this situation.

but also by other factors that imposed a deceleration effect on the
rate of decline in poverty long before COVID-19 came along, such
as armed conﬂicts and environmental disasters linked to the effects of climate change (World Bank, 2020). If these poverty trends
continue the prospects for achieving the global targets for ending
TB are indeed grim.

Tuberculosis ﬁnancing
The delivery of effective TB care and prevention interventions
demands that adequate resources are mobilized to facilitate wide
coverage of the population with these interventions in addition
to identifying new tools (research to identify new diagnostics and
treatment ) and new ways of delivering existing interventions
through operations and implementation research. The 2021 WHO
global TB report (WHO,2021) highlights a major annual global
funding gap. Of the annual need of about USD 13 billion, only 5.3
billion USD was available for TB care and prevention in 2020 and
of the 2 billion USD required for TB research , only USD 901 million was available in 2020. With these huge funding gaps in TB
care and prevention, it is not surprising that slow progress is being made towards the attainment of the ambitious End TB Strategy
and UNHLM TB targets. What is the main reason for the chronic
underfunding for TB? Is it that global TB advocates aren’t doing
enough or not doing the right thing? Why have targets of TB advocacy not responded appropriately?
We believe that the COVID-19 pandemic has important lessons
for TB advocacy and TB ﬁnancing. It appears fortuitous that many
high TB burden settings have not experienced the full wrath of
the COVID-19 pandemic. For example, by the end of January 2022,
sub-Saharan Africa (SSA) had contributed only 1.5% of all conﬁrmed SARS-COV 2 infections and about 3% of all COVID-19 deaths
(WHO COVID-19 Dashboard) a situation that cannot be fully explained by non or under identiﬁcation and reporting of SARS –
COV2 infections and COVID-19 deaths in this continent. The COVID19 pandemic has brought to the fore the inequities in global
health: high income countries rapidly mobilized ﬁnancial resources
that led to the development of diagnostic tests, medicines and
novel vaccines at such a speed that has never been seen before.
While this is great for global public health and public good, the
fact that most of these tools remain unavailable for large sections
of the population in low resource settings is cause for concern
(Bolcato, et al, 2021). The burden of TB is higher in low resource
settings and within those settings the poor suffer even more. If the
inequities being observed with COVID-19 diagnostics, treatment,
and preventive tools (vaccines) is a reﬂection of human thinking
and behavior, then we should resign to the fact TB will be with us
for a long time to come, certainly it will not have ended by 2035.
This would be shameful and should be stopped. We hope that TB
advocates at all levels will use the lessons from the COVID-19 pandemic to craft new ways of telling the TB story to support mobilization of adequate resources to ﬁght this disease. We need to end
inequities in the TB response.
In conclusion while the data presented by 2021 WHO global TB
report show a deteriorated scenario, we believe that the tide can
be changed. We have reﬂected on the status of the global burden
of TB, the strategies, and interventions in place for confronting TB
and the progress being made with TB care and prevention targets
as presented in the 2021 WHO global TB report. It is still feasible
to achieve the ambitious End TB Strategy targets in the remaining time. This will require global solidarity with nations becoming
each other’s keeper, enhanced application of current interventions
and tools and doubling of efforts to fund and support TB research
and innovation. Improving the resilience of health systems will be
key in achieving the set targets. The clock is ticking, and humanity

Social determinants
It is well known that TB is a poverty driven disease and therefore addressing social determinants of the disease was included as
a critical component of pillar 2 of the End TB Strategy. While it
may be argued that addressing social determinants of TB is not
a direct remit of TB care and prevention programs, these governmental agencies need to be linked with and if feasible drive
processes for the development and implementation of multi sectoral approaches that support TB prevention at the population
level. The WHO has been working hard to push countries to develop multi -sectoral approaches to TB care and prevention including the development of appropriate accountability frameworks
(WHO, MAF- TB). Whether effective TB multi-sectoral accountability frameworks in high TB burden settings are in place and the
impact they are having on local TB responses is currently unclear.
It is certain that TB care and prevention targets are unlikely to be
achieved if large proportions of the populations of the world are
allowed to continue languishing in poverty and at a high social risk
of exposure to the TB bacillus and progression to active TB disease
on account of under- nutrition, poor housing, socially driven substance abuse and poor access to health services. Unfortunately, this
is the situation that the world ﬁnds itself today. Global poverty
rates rose, with an estimated 119-124 people pushed back to extreme poverty in 2020, driven partly by the COVID-19 pandemic
3
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should tick even more to invest to End TB , save lives and make TB
history (WHO 2022).
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